Skip to main content
See every side of every news story
Published • loading... • Updated

Lavipharm: 12.5% Increase in EBITDA From Continuing Operations

Summary by iatronet.gr
Consolidated sales before Clawback & Rebates amounted to €61.10 million compared to €47.74 million in the corresponding period last year, recording an increase of 28%.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

Lavipharm announced the key consolidated financial figures for the first nine months of 2026, recording a 12.5% increase in adjusted earnings before interest, taxes, depreciation and amortization (

Capital.grCapital.gr
Reposted by
iatronet.griatronet.gr

Total profits after taxes from continuing and discontinued operations amounted to Euro 4.02 million, recording an increase of 14.3%.

Consolidated Sales before Clawback & Rebates amounted to Euro 61.10 million compared to Euro 47.74 million in the corresponding period last year, recording an increase of 28%.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

insider.gr broke the news on Thursday, November 19, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal